Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics Inc., it pioneered the use of recombinant DNA technology to develop biologic medicines.
The company discovers, develops, manufactures, and markets human therapeutics for serious illnesses, including cancer, cardiovascular disease, osteoporosis, inflammatory conditions, and rare diseases. Key products include Prolia and Xgeva (denosumab) for bone diseases, Enbrel (etanercept) for autoimmune disorders, Repatha (evolocumab) for hyperlipidemia, Otezla (apremilast) for psoriasis, Tepezza (teprotumumab) for Graves' ophthalmopathy, Kyprolis (carfilzomib) for multiple myeloma, and others such as Aranesp, Neulasta, and Nplate.
Amgen operates in approximately 100 countries with manufacturing facilities in the US, Puerto Rico, Ireland, the Netherlands, and Singapore. It is publicly traded on Nasdaq (AMGN) and ranks among the largest biomedical companies by revenue.
